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Aims The epidemiology of the five stages of chronic kidney disease (CKD) in systolic heart failure (HF) patients has pre-
dominantly been described in hospitalized White patients, with little known about the prevalence in outpatient Blacks
and Hispanics. The purpose of this study was to compare the prevalence of the five stages of CKD by race, ethnicity




We conducted a prospective study of 1301 patients recruited from two hospital facilities in Louisiana and Florida,
USA. All patients were enrolled in a systolic HF disease management programme (HFDMP), which enrolled patients
with an ejection fraction of ≤40% by echocardiography. The estimated glomerular filtration rate was calculated using
the abbreviated Modification of Diet in Renal Disease Study equation. Patients were classified into five stages of CKD
according to the National Kidney Foundation classification system. A total of 338 patients (26%) were found to have
CKD. Patients with CKD were older, more likely to be Hispanics, to have less education, New York Heart Associ-
ation class III, elevated systolic blood pressure, and diabetes. There was no statistical difference in prevalence by
gender. Survival was reduced in patients with CKD.
Conclusion The prevalence of CKD in an outpatient systolic HFDMP is high, with over one in four patients affected. CKD patients
had significantly lower survival rates compared with patients without CKD.
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Introduction
In 2002, the National Kidney Foundation Disease Outcomes
Quality Initiative (KDOQI) published guidelines to establish a
new nomenclature system, in which all patients with persistent
proteinuria or a glomerular filtration rate (GFR) ,60 mL/min/
1.73 m2 for at least 3 months independent of the underlying path-
ology are classified as having chronic kidney disease (CKD).1 The
National Kidney Foundation classification system stratifies patients
with CKD into five stages according to the level of GFR. Using this
staging classification, the Third National Health and Nutrition
Examination Survey (NHANES III) reported that CKD affects
19.2 million of the US adult population (16.8%). By stages, an esti-
mated 5.9 million individuals have Stage 1 CKD; 5.3 million have
Stage 2; 7.6 million have Stage 3; 400 000 individuals have Stage
4, and 300 000 individuals have Stage 5 CKD which is an end-stage
renal disease (ESRD).
Chronic kidney disease and HF share several risk factors and
pathogenic pathways such as hypertension, diabetes, and the acti-
vation of the renin–angiotensin–aldosterone system.2 Chronic
kidney disease is becoming a highly prevalent condition among
patients with HF, with a significant number of patients progressing
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to ESRD.3 According to the American Heart Association 2009
Statistics, the 2006 prevalence of HF in the USA was 5.7 million
with 3.2 million men and 2.5 million women affected by this
disease.4
The prevalence of CKD in HF populations has been described
mainly in an inpatient setting, and there seems to be a paucity of
data about the prevalence of CKD in HF outpatients. Therefore,
the purpose of this study was to examine the prevalence of
CKD by ethnicity, race, and gender in an outpatient heart failure
disease management programme (HFDMP), and also to evaluate
the impact of CKD on mortality within this population.
Methods
Patients
We conducted a prospective cohort study that included patients from
two outpatient health care facilities in Louisiana and Florida, USA. All
patients were enrolled in a HFDMP, and all had an ejection fraction
(EF) of ≤40% by echocardiography.
The Louisiana site was at the Leonard J. Chabert Medical Center
(LJCMC), which is a rural safety-net hospital located in south Louisiana
providing care primarily to uninsured and underinsured patients with a
severely depressed socioeconomic (SES) background (more than 55%
of patients were 200% below the federal poverty level). Recruitment
of study participants took place from August 1999 to December 2007.
At the Florida site, patient enrolment took place from September
2007 to January 2009 at Jackson Memorial Hospital which is a large,
urban 1600-bed safety-net hospital located in Miami, Florida. The
patient population served at this hospital is largely indigent; 43% of
patients in this study were classified as indigent and did not have any
type of insurance, 38% had either Medicare or Medicaid, and the
remaining 19% had private insurance. In addition, the patient popu-
lation at this facility was largely comprised of immigrants, with 98%
born outside the U.S. Institutional Review board approval was
obtained from the University of Miami-Miller School of Medicine and
the Louisiana State University Health Sciences Center. All patients
gave written informed consent to have their data included in an elec-
tronic data registry.
Definitions and outcomes
Patients identified as having eGFR ,60 mL/min/1.73 m2 were classified
as having CKD (CKD group), whereas patients identified as having
eGFR ≥ 60 mL/min/1.73 m2 were classified as not having CKD or
non-CKD group.
The KDOQI working group defined CKD in adults as evidence of
structural or functional kidney abnormalities (abnormal urinalysis,
imaging studies, or histology) that persist for at least 3 months, with
or without a decreased GFR (as defined by a GFR of ,60 mL/min/
1.73 m2).5 Laboratory tests performed closest to the date of enrol-
ment into the clinic were used to stratify patients. Two blood
samples taken at least 3 months apart were used to define CKD.
The most common manifestation of kidney damage is persistent
albuminuria, including microalbuminuria.6 The normal rate of albumin
excretion is ,20 mg/day (15 mg/min). Persistent albumin excretion
between 30 and 300 mg/day (20–200 mg/min) is called microalbumi-
nuria. Urinalysis performed closest to the date of enrolment was
used to assess the presence of proteinuria.
The eGFR was calculated using the abbreviated Modification of Diet
in Renal Disease Study equation:5,7 eGFR (mL/min/1.73 m2) ¼ 186 ×
(serum creatinine in mg/dL)21.154 × (age in years)20.203 × 0.742 in
female subjects × 1.210 in black subjects.
Patients were classified into five stages of CKD in accordance with
the classification of the National Kidney Foundation (Table 1).
The online Social Security Death Index was used in order to obtain
all-cause mortality data. Mortality was assessed up to 31 December
2009.
Statistical analysis
The overall CKD prevalence and prevalence by ethnic/race and gender
were calculated. Ethnic/race and gender differences in CKD prevalence
were analysed using the x2 test. Demographic and other clinical
characteristics were compared between patients with CKD and
those without CKD. For categorical variables, a x2 test was used to
evaluate group differences. For continuous variables, analysis of var-
iance was used to evaluate between-group differences. Survival was
estimated by the Kaplan–Meier curves product– limit method and
was compared between the two groups (patients with CKD and
patients without CKD) with the x2 test. Careful consideration was
taken to avoid pitfalls in the survival plots of time to event data.8
The number of cases at risk was calculated as the number of cases
that entered the respective interval alive minus half of the number
of cases lost or censored in the respective interval. Unadjusted survival
rates are presented and compared with P for trend and x2. For the
adjusted analysis, we used two methods. First, we calculated the
hazard ratio (HR) of death for subjects with CKD adjusting for EF,
type of cardiomyopathy, use of angiotensin-converting enzyme
(ACE) inhibitors and beta-blockers, and diabetes using Cox pro-
portional models. We did not include demographic variables in our
multivariate model because they were accounted for in the eGFR cal-
culation. The second method was a Cox proportional model that
included CKD stages as a dummy variable, for this analysis we used
Stage 1 CKD as the reference value. All analyses were conducted
using SAS 9.1, all tests were two-tailed, and a P-value of ,0.05 was
considered statistically significant.
Results
The study population consisted of 1301 patients. A total of 338
patients (26%) with HF were found to have CKD. Demographic
and clinical characteristics according to the presence or absence
of CKD are presented in Table 2. CKD patients were more likely
to be older, to be of Hispanic ethnicity, to have less education,
to have a higher NYHA class, to have diabetes, and higher systolic
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Table 1 Staging of chronic kidney disease according to
the National Kidney Foundation classification system
Stage Description GFR, mL/min/
1.73 m2
1 Kidney damage with normal or 
GFR
≥90
2 Kidney damage with mild  GFR 60–89
3 Moderate  GFR 30–59
4 Severe  GFR 15–29
5 Kidney failure ,15 (or dialysis)
GFR glomerular filtration rate.
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blood pressure (SBP) in comparison with non-CKD patients.
Chronic kidney disease patients were also less likely to be pre-
scribed ACE inhibitors.
Chronic kidney disease was more prevalent in men than in
women although this difference was not statistically significant.
Table 3 shows the prevalence of CKD and survival percentage by
CKD stage during the period of the study. Patients in Stage 1 CKD
had the highest survival rate. The lowest survival rate was found in
patients in Stage 4 and 5 CKDs, which was marginally significant
compared with Stage 1 CKD (P ¼ 0.075). Although mortality con-
sistently increases at each stage of CKD, this trend was not statisti-
cally significant (P ¼ 0.059).
One hundred and six patients died after enrolment into the
HFDMP. The survival curve (Figure 1) shows that CKD patients
had significantly lower survival rates compared with patients
without CKD (x2 for 1 dof P ¼ 0.04). The survival of heart
failure patients worsened with worsening CKD stage.
The adjusted HR of death for patients with CKD was 1.29 (95%
CI 0.81–2.05), P ¼ 0.27. When each stage of CKD was evaluated
individually in the multivariate model, we found a graded increase
in the risk of death and that Stage 4 had an HR of 2.4 (95% CI
1.01–6.11), P ¼ 0.04.
Discussion
This study examined the prevalence of CKD across three race/
ethnic groups of HF patients as well as by gender. We found
that the prevalence of CKD was high with over one in four HF
patients affected.
In contrast to previous studies, we found that the prevalence of
CKD was higher among Hispanics in our sample. In the literature,
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Table 2 Demographic characteristics of chronic kidney disease compared to non-chronic kidney disease patients
Variable CKD (n 5 338) Non CKD (n 5 963) P-value
Age, years (SD) 62 (12) 54 (11) ,0.001
Gender
Female, n (%) 109 (32%) 347 (36%) X2 ¼ 1.57; P ¼ 0.210
Male, n (%) 229 (68%) 616 (64%)
Race
White, n (%) 132 (39%) 408 (42%) X2 ¼ 9.38; P ¼ 0.009
Hispanic, n (%) 86 (25%) 171 (18%)
Black, n (%) 120 (36%) 384 (40%)
Education level
Elementary school (0–5 years) 57 (19%) 111 (12%) X2 ¼ 8.51; P ¼ 0.014
High school (6–12 years) 205 (68%) 675 (75%)
Post high school (more than 12 years) 38 (13%) 111 (12%)
NYHA, n (%)
Class 1 66 (20%) 260 (28%) X2 ¼ 8.69; P ¼ 0.034
Class 2 113 (35%) 317 (34%)
Class 3 114 (35%) 267 (29%)
Class 4 32 (10%) 92 (10%)
Systolic blood pressure, mmHg (SD) 135 (29) 130 (25) 0.002
Diastolic blood pressure, mmHg (SD) 79 (18) 79 (17) 0.775
Ischaemic cardiomyopathy, n (%) 278 (82%) 774 (80%) X2 ¼ 0.5; P ¼ 0.451
Diabetes, n (%) 143 (42%) 291 (30%) X2 ¼ 16.4; P ¼ ,0.001
Mean EF, % (SD) 28 (10) 29 (11) 0.250
Mean eGFR, mL/min per 1.73 m2 (SD) 42 (15) 94 (31) ,0.001
Beta blocker, n (%) 326 (96%) 929 (97%) X2 ¼ 0.08; P ¼ 0.777
ACE/ARB, n (%) 291 (91%) 898 (95%) X2 ¼ 6.73; P ¼ 0.009
Spironolactone, n (%) 56 (17%) 200 (21%) X2 ¼ 2.79; P ¼ 0.095
Digoxin, n (%) 71 (21%) 245 (25%) X2 ¼ 2.67; P ¼ 0.102
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Prevalence of chronic kidney disease and
survival according to chronic kidney disease stage
CKD stage Prevalence of stage, n (%) % survival
1 449 (34.5) 93.3
2 514 (39.5) 91.8
3 267 (20.5) 90.6
4 47 (3.6) 87.2
5 24 (1.5) 87.5
P-value x2 (4 dof) ¼ 0.23; P-value trend (4 dof) ¼ 0.059.
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the prevalence of CKD among non-Hispanic blacks and Mexican
Americans is higher in comparison with non-Hispanic Whites.9
The lack of concordance between our results and reports from
previous studies may be attributed to differences in the study
populations and associated risk factors. The Hispanic group in
our sample was composed mainly of Cuban descendents and
very few Mexican Americans, who represents the majority of His-
panics in the USA, were enrolled.
Past studies have reported a higher prevalence of CKD in males
in comparison with females. Our results are in concordance with
these reports;10 however, in our sample, this difference was not
statistically significant.
Our results further support an association between diabetes and
CKD since the prevalence of CKD was clearly higher among our
diabetic patients. As a matter fact diabetes mellitus, types 1 and
2, is the leading cause of incident and prevalent CKD, accounting
for 30–40% of CKD and up to 45% of ESRD.11
In this study, SBP was higher among CKD patients. Hypertension
is one of the leading causes of ESRD in Europe and in the United
States. Previous research has identified hypertension as an inde-
pendent risk factor in the development and progression of
CKD.11–13 Furthermore, in a study by Young et al.,13 SBP was
identified as a strong predictor of a decline in kidney function
among patients aged ≥70 years. Moreover, the risk of kidney dys-
function was strongly associated with SBP, when compared with
diastolic blood pressure and mean arterial pressure. However, in
contrast to previous studies,9 we did not find statistically significant
differences in the prevalence of ischaemic cardiomyopathy.
Regarding medications, the use of ACE inhibitor and
angiotensin-receptor blocker was more prevalent among
non-CKD patients, which is not surprising since the use of these
drugs is sometimes prohibited in patients with a decreased
GFR.14,15
In our study, CKD was more prevalent among those with lesser
educational attainment. Several other authors16– 19 have previously
described an association between lower SES and educational
achievement and progressive CKD.
In agreement with the findings from the majority of previous
studies, we found that patients with more severe kidney dysfunc-
tion have higher mortality than patients with less severe kidney
impairment10 as shown by decreased survival among patients in
CKD Stages 4 and 5.
Our study has some limitations. The study population was
mainly from a low SES background and were either uninsured or
underinsured; therefore, it is unclear whether the results from
this study could be generalized to Whites, Blacks, and Hispanics
with a higher SES background or with private insurance.
The Hispanic patients in this study were primarily Cuban in
origin. Although Cubans represent a majority in Miami, Mexican
Americans represent the majority of Hispanics in the USA so
again; these results may not be applicable to Hispanics in the
USA in general.
Understanding the role of renal impairment in HF could provide
more precise risk stratification, prognostication and, ultimately, the
development of optimal therapeutic strategies. The precise magni-
tude of these risk factors are not known, however, given the
Figure 1 Kaplan–Meier cumulative survival curve by chronic kidney disease.
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growing incidences of HF and CKD, both exceptionally costly and
morbid conditions, it is important to acknowledge the magnitude
of this problem.
Conclusion
Chronic kidney disease affects more than one in four patients from
an outpatient systolic HF population, which is higher than the
prevalence of CKD in the general population. Chronic kidney
disease patients have significantly lower survival rates compared
with patients without CKD. It is vital to understand the best
method of estimating and characterizing renal impairment among
HF patients as well as defining effective management strategies
since this can have an impact on their survival.
Conflict of interest: none declared.
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